Evidence map›Paper›PMID 33927241›Full record

ArticleScientific reports2021

Surface Modified β-Tricalcium phosphate enhanced stem cell osteogenic differentiation in vitro and bone regeneration in vivo.

Cheuk Sing Choy, Wei Fang Lee, Pei Ying Lin, Yi-Fan Wu, Haw-Ming Huang, Nai-Chia Teng, Yu-Hwa Pan, Eisner Salamanca, Wei-Jen Chang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Cheuk Sing ChoyDepartment of Community Medicine, En Chu Kong Hospital, New Taipei City, Taiwan.
Wei Fang LeeSchool of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Pei Ying Lin *School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Yi-Fan Wu *School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Haw-Ming HuangDepartment of Community Medicine, En Chu Kong Hospital, New Taipei City, Taiwan.
Nai-Chia TengDepartment of Community Medicine, En Chu Kong Hospital, New Taipei City, Taiwan.
Yu-Hwa PanSchool of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
Eisner SalamancaSchool of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan. eisnergab@tmu.edu.tw.
Wei-Jen ChangSchool of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan. cweijen1@tmu.edu.tw.
Taipei Medical University · TWChang Gung Memorial Hospital · TWEn Chu Kong Hospital · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major number of studies have demonstrated Beta-tricalcium phosphate (β-TCP) biocompatibility, bioactivity, and osteoconductivity characteristics in bone regeneration. The aim of this research was to enhance β-TCP's biocompatibility, and evaluate its physicochemical properties by argon glow discharge plasma (GDP) plasma surface treatment without modifying its surface. Treated β-TCP was analyzed by scanning electron microscopy (SEM), energy-dispersive spectrometry, X-ray photoelectron spectroscopy (XPS), X-ray diffraction analysis, and Fourier transform infrared spectroscopy characterization. To evaluate treated β-TCP biocompatibility and osteoblastic differentiation, water-soluble tetrazolium salts-1 (WST-1), immunofluorescence, alkaline phosphatase (ALP) assay, and quantitative real-time polymerase chain reaction (QPCR) were done using human mesenchymal stem cells (hMSCs). The results indicated a slight enhancement of the β-TCP by GDP sputtering, which resulted in a higher Ca/P ratio (2.05) than the control. Furthermore, when compared with control β-TCP, we observed an improvement of WST-1 on all days (p < 0.05) as well as of ALP activity (day 7, p < 0.05), with up-regulation of ALP, osteocalcin, and Osteoprotegerin osteogenic genes in cells cultured with the treated β-TCP. XPS and SEM results indicated that treated β-TCP's surface was not modified. In vivo, micro-computed tomography and histomorphometric analysis indicated that the β-TCP test managed to regenerate more new bone than the untreated β-TCP and control defects at 8 weeks (p < 0.05). Argon GDP treatment is a viable method for removing macro and micro particles of < 7 μm in size from β-TCP bigger particles surfaces and therefore improving its biocompatibility with slight surface roughness modification, enhancing hMSCs proliferation, osteoblastic differentiation, and stimulating more new bone formation.

Indexed as

AnimalsBiocompatible MaterialsCalcium PhosphatesCell DifferentiationCell ProliferationCells, CulturedHumansIn Vitro TechniquesMaleMesenchymal Stem CellsModels, AnimalOsteogenesisRabbitsSurface PropertiesTissue EngineeringX-Ray Microtomographybeta-tricalcium phosphateBiocompatible MaterialsCalcium Phosphates

Identifiers

PMID33927241
PMCPMC8084957
OpenAlexW3158576772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.